This study will evaluate the efficacy and safety of elexacaftor (ELX) / tezacaftor (TEZ) / ivacaftor (IVA) triple combination (TC) in subjects 6 through 11 years of age with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function (MF) mutation (F/MF genotypes).
|Treatment||Placebo, IVA, ELX/TEZ/IVA|
|Clinical Study Identifier||NCT04353817|
|Sponsor||Vertex Pharmaceuticals Incorporated|
|Last Modified on||23 December 2020|
Select a piece of text and start making personal notes.
Congrats! You have your own personal workspace now.